ArticlePloS one2026
Meningococcal disease epidemiology - United States, 2020-2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh quality surveillance data are important to monitor changes in incidence and better understand risk factors for meningococcal disease. This report summarizes meningococcal disease epidemiology from 2020 through 2023 in the U.S.
methodsEpidemiologic information and isolates obtained through Enhanced Meningococcal Disease Surveillance for meningococcal disease cases reported through the National Notifiable Diseases Surveillance System (NNDSS) during 2020-2023 were included in the analysis. Isolates were characterized by serogrouping and molecular typing using whole genome sequencing.
resultsA total of 1,192 confirmed and probable meningococcal disease cases were reported through NNDSS during 2020-2023. Incidence was highest in 2023 (0.13 cases per 100,000) and lowest in 2021 (0.06 cases per 100,000). The proportion of cases that were serogroup Y increased over time, accounting for 56.8% of cases in 2023 compared to 16.0% in 2021. For serogroup Y, the most common clonal complex (CC) was CC23 in 2020-2021 and CC174 in 2022-2023. Prior to 2022, CC174 was rare in the U.S., accounting for less than 10% of serogroup Y cases, but in 2022-2023, CC174 accounted for more than 60% of serogroup Y cases. Nine outbreaks began in 2020-2023 and included 109 cases. The proportion of cases associated with outbreaks ranged from 0.9% in 2020 to 26.2% in 2022.
conclusionsMeningococcal disease incidence continued to decline during the COVID-19 pandemic but increased to above pre-COVID-19 pandemic incidence by 2023. It will be important to continue to monitor meningococcal disease incidence, especially of serogroup Y, over the next several years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.